Two sensitive and selective analytical methods were developed for simultaneous determination of aminoacridine hydrochloride and lidocaine hydrochloride in bulk powder and pharmaceutical formulation. Method A was based on HPLC separation of the cited drugs with determination of the toxic lidocaine-related impurity 2,6-dimethylaniline. The separation was achieved using reversedphase column C18, 250 × 4.6 mm, 5 µm particle size and mobile phase consisting of 0.05 M disodium hydrogen phosphate dihydrate ( pH 6.0 ± 0.2 adjusted with phosphoric acid) and acetonitrile (55 : 45, v/v). Quantitation was achieved with UV detection at 240 nm. Linear calibration curve was in the range of 1.00-10.00, 13.20-132.00 and 1.32-13.20 µg mL −1 for aminoacridine hydrochloride, lidocaine hydrochloride and 2,6-dimethylaniline, respectively. Method B was based on TLC separation of the cited drugs followed by densitometric measurement at 365 nm on the fluorescent mode for aminoacridine hydrochloride and 220 nm on the absorption mode for lidocaine hydrochloride. The separation was carried out using ethyl acetate-methanol-acetic acid (65 : 30 : 5 by volume) as a developing system. The calibration curve was in the range of 25.00-250.00 ng spot −1 and 0.99-9.90 µg spot −1 for aminoacridine hydrochloride and lidocaine hydrochloride, respectively. The results obtained were statistically analyzed and compared with those obtained by applying the manufacturer's method.
Introduction
Aminoacridine (aminacrine) hydrochloride monohydrate (ACR) is chemically known as 9-aminoacridine (1). It is a mild antiseptic that kills a variety of bacteria that might infect sore or broken skin in the mouth (2). 9-Aminoacridines are the most active and stronger bases than other aminoacridines (3) .
Lidocaine (lignocaine) hydrochloride monohydrate (LID) is chemically known as 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide. It belongs to a group of medicines known as local anesthetics (4) . When applied locally, it works by stopping the sodium entering the nerve ending at the site of the pain. This prevents an electrical signal building up and passing along the nerve fibers to the brain. In this way, lidocaine causes numbness and relieved pain at the area it was applied to. For the anesthetic activity, the existence of a balance between the lipophilic and hydrophilic parts of the molecule is essential (3).
The combination of ACR and LID is found in pharmaceutical formulation Medijel ® oral gel. The antiseptic ACR prevents the irritated areas from getting infected, and LID is used to relieve pain caused by mouth ulcers, sore gums and denture irritation. There were no reported methods for their simultaneous determination. Few spectrophotometric, fluorimetric and TLC methods (5-7) were reported for determination of ACR. A lot of methods were reported for determination of LID, for example, some of the latest methods include spectrophotometry (8) (9) (10) , electrochemical (11) (12) (13) , HPLC (14) (15) (16) (17) (18) (19) (20) and capillary electrophoresis (21) (22) (23) (24) . The novelty of this research was to develop HPLC and TLC-densitometric methods for simultaneous determination of ACR and LID in their binary mixture as there were no reported methods for their simultaneous determination. There was also a need for the detection and determination of the toxic lidocaine-related impurity if present with the cited mixture.
2,6-Dimethylaniline (DMA) is a yellowish liquid stated in British Pharmacopoeia (25) as major impurity of lidocaine in bulk powder and dosage forms. It is also used in the synthesis of LID (26) and considered to be its major degradation product (27) , which is a pharmacologically inactive metabolite (28) . It is absorbed through the skin and mucosa causing damage to the following organs: blood, kidneys, liver and heart, causing arrhythmias, tachycardia and heart block. It is mutagenic causing methemoglobinemia including hypoxia, apnea and cyanosis (a bluish discoloration of the skin due to deficient oxygenation) (29) . It may cause nasal olfactory mucosa cancer and classified as Class 2B ( possible for human) (30) . Its chemical cancer potency is 0.0063 mg/(kg body weight-day) −1 estimated from dose-response data for nasal cavity tumors in male and female rats (31, 32) .
Experimental
Instruments (i) HPLC Agilent model 1200 was equipped with a quaternary pump, Rheodyne injector with a 20-µL loop and UV detector (Germany). Separation and quantitation were made on ACE C18-AR, 250 × 4.6 mm, 5 µm particle size column. The detector was set at 240 nm. The instrument was connected to an IBM compatible PC and HP disk jet printer. (ii) Reversed-phase TLC 20 × 20 cm aluminum sheets precoated with silica gel F 254 , 0.25 mm thickness, Merck (Germany), were used. The samples were applied to the plate using 25 µL Hamilton Analytical Syringe. (iii) CAMAG dual wavelength flying spot densitometer was used with video display and high-speed, high-quality, parallel-head printer plotter (Switzerland). The instrument was connected to an IBM compatible PC and HP disk jet printer. The following requirements were taken into consideration-the measuring mode: fluorescent for the determination of ACR and absorbance for the determination of LID; slit dimensions: 4 × 0.3 mm; scanning speed: 20 mm s
; data resolution: 100 µm per step; optimize optical system for maximum: light; band width: 20 mm and result output: chromatogram and area under the peak. (iv) pH meter HANAA 8417 (Portugal) was used.
Materials and chemicals
Pure standard ACR was kindly supplied by Sigma-Aldrich; its purity was 99.30% according to the manufacturer's HPLC method.
LID was kindly supplied by Al Deibeiky Pharma, Egypt; its purity was 99.97% according to the USP (33) method.
Lidocaine-related impurity (DMA) was kindly supplied by Sigma-Aldrich, and its purity was 99.97%. 
TLC-densitometric method
The analysis was performed on 20 × 20 cm TLC aluminum sheets precoated with silica gel F 254 , 0.25 mm thickness. A volume of 5 µL of different concentrations of standard solutions of ACR and LID was applied as spots to the plate using 25 µL Hamilton Analytical Syringe. The spots were spaced 20 mm apart and 20 mm from the bottom of the plate. The chromatographic chamber was presaturated with the developing system for 15 min, and the plate was developed by ascending chromatography using ethyl acetate-methanol-acetic acid (65 : 30 : 5 by volume) as a developing system to the distance of 14 cm. The plate was air-dried at room temperature, detected under UV lamp and scanned at 365 and 220 nm for ACR and LID, respectively. tively. Triplicate applications were made for each solution, the plates were chromatographed as mentioned above and the peak areas were measured. The calibration curves of ACR and LID were constructed, and the regression equations were computed.
Standard solutions

HPLC method
Preparation of pharmaceutical formulation
HPLC method An accurately weighed 4 g of the gel (equivalent to 2.0 mg of ACR and 26.4 mg of LID) was transferred into a 100-mL volumetric flask; 70 mL of the solvent was added and dissolved by the aid of magnetic stirrer for 20 min. The volume was completed to the mark with the solvent mixture and filtered to obtain stock solution of final concentration 20.0 µg mL −1 of ACR and 264.0 µg mL −1 of LID.
TLC-densitometric method
An accurately weighed 6 g of the gel (equivalent to 3.0 mg of ACR and 39.60 mg of LID) was transferred into a 100-mL volumetric flask, and ∼70 mL of methanol was added. The procedure was followed as under construction of calibration curve to obtain stock solution of final concentration 30.0 µg mL −1 of ACR and 396.0 µg mL −1 of LID.
The sample solutions were then filtered using 0.45 µm filters. The general procedures for HPLC and TLC-densitometric methods described under construction of calibration curves were followed, and the concentrations of ACR and LID were calculated.
Pharmaceutical formulation stability under mild acid and alkali conditions
An accurately weighed 4 g of the gel was transferred into a 100-mL volumetric flask; 70 mL of 0.1 M acetic acid was added and dissolved by the aid of magnetic stirrer for 20 min. The volume was completed to the mark with the same solvent and filtered. The solution was left for 3 h at 20°C. The general procedure for the proposed HPLC method described under construction of calibration curves was followed.
Another solution was prepared with the same manner using 0.01 M sodium carbonate instead of acetic acid.
Results
The best resolution with sharp and symmetric peaks for the HPLC method was obtained using mobile phase of 0.05 M disodium hydrogen phosphate dihydrate ( pH 6.0 ± 0.2 adjusted with phosphoric acid) and acetonitrile (55 : 45, v/v, Figure 1A ). Good separation of ACR, LID and DMA from the inactive ingredients of the pharmaceutical formulation was done. The retention times of ACR, LID and DMA were found to be 2.97, 4.71 and 8.85 ± 0.2 min, respectively, as shown in Figure 1B . System suitability parameters of the proposed HPLC method were calculated according to the USP (33) showing good resolution, selectivity and symmetrical peaks (Table I) . For the TLC-densitometric method, good separation was obtained using ethyl acetate-methanol-acetic acid (65 : 30 : 5 by volume) as a developing system. The retardation factors (R f ) of ACR and LID were found to be 0.40 ± 0.03 and 0.18 ± 0.03, respectively, as shown in Figures 2 and 3 .
Method validation was performed according to ICH guidelines (34) for the proposed HPLC and TLC-densitometric methods. The results of the proposed methods validation are shown in Table II , indicating good accuracy, repeatability and intermediate precision.
Characteristic parameters for the regression equations of the proposed methods and the correlation coefficients, obtained by least squares treatment of the results, are also given in Table II . The proposed methods could be used for routine analysis of ACR and LID in laboratory prepared mixtures (Table III) . Table IV shows that the proposed methods were also applied for determination of the cited drugs in their pharmaceutical formulation Medijel ® oral gel in quality control laboratories without interference from the excipients. The pharmaceutical formulation was subjected to 0.1 M acetic acid and 0.01 M sodium carbonate left for 3 h at 20°C and analyzed by the proposed HPLC method. ACR and LID were found to be 97.98 The ratio of ACR and LID similar to pharmaceutical formulation.
and 95.00%, respectively. The impurity DMA was detected to be 0.24 μg mL −1 as shown in Figure 4 .
Statistical comparison of the results of ACR and LID analysis obtained by the proposed methods and the manufacturer one was also done using Student's t-test and the F-ratio at 95% confidence level (Tables IV and V) . It was clear that there was no significant difference between the proposed methods with regard to accuracy and precision. showing the impurity DMA (∼0.24 μg mL −1 ) and other inactive substances.
Discussion
The proposed HPLC and TLC-densitometric methods were used for simultaneous determination of ACR and LID in their pharmaceutical formulation without either pretreatment or preliminary separation. Besides, the HPLC method was used for determination of lidocaine-related impurity, DMA, which is a pharmacologically inactive metabolite (28) . It is absorbed through the skin and mucosa causing damage to the following organs: blood, kidneys, liver and heart, causing arrhythmias, tachycardia and heart block. The British Pharmacopoeia (25) stated that the limit of LID impurity was 0.01%, so it is important to be determined in LID pharmaceutical formulations. Lidocaine hydrochloride has an amide linkage, which is susceptible to hydrolysis and thermal degradation to this impurity (DMA) (35) . The impurity will increase by time because lidocaine degradation is firstorder kinetics (36) .
HPLC method
Several trials were carried out to obtain a good resolution between the cited components. These trials involved the use of different mobile phases with different ratios, different pH and flow rates. The pH of the mobile phase was very critical, affecting the retention time of ACR, LID and DMA. At pH 3.0, ACR was not well separated, and LID and DMA were separated at retention times 5.80 and 7.00 min, respectively. By increasing the pH to 8.0, ACR was separated at 3.80 min, and the retention time of LID and DMA was delayed to be 16.70 and 10.00 min, respectively. Therefore, the optimum pH was 6.0 ± 0.2 to ensure best separation of the three cited components from each other and from the inactive ingredients in the pharmaceutical formulation.
Several wavelengths were tested (210, 220, 230, 240, 250 and 260 nm). The most suitable wavelength was 240 nm to detect the three components, especially DMA. The mobile phase was delivered at different rates (0.8, 1.0 and 1.5 mL min ), and the optimum one was 1.0 mL min −1 , which provides maximum separation with minimum run time. Robustness was done by changing the pH (±0.2), flow rate (±0.1 min) and ratio of the mobile phase (±2%) as shown in Table II . The proposed HPLC could determine ACR and LID in their pharmaceutical formulation without interference from the inactive ingredients. It was capable for the detection and determination of the lidocaine-related impurity (DMA) as it is very toxic. The separation of the cited compounds by the proposed method was done in short time before 10 min.
The impurity if present in pharmaceutical formulation due to bad storage condition, the proposed HPLC will detect it with minimum detection level of 0.22 µg mL −1 . When the pharmaceutical formulation was subjected to acetic acid and sodium carbonate as an example of mild conditions of acid and alkali, this impurity was formed besides ACR and LID were in the range of 90-110% of their labeled claim. The advantages of the proposed HPLC method over the manufacturer one were the higher sensitivity of ACR and the capability of the determination of DMA. The proposed HPLC method had advantage over the reported one (19) of separating ACR from the inactive ingredients in the pharmaceutical formulation. Also, the proposed HPLC method separated LID faster than the British Pharmacopoeia method (25).
TLC-densitometric method
Different parameters that affect the efficiency of the chromatographic separation were tested and optimized to obtain maximum separation of the cited components. The TLC-densitometric method was optimized to be capable of separating ACR and LID.
Many trials were done to choose a developing system that can affect the separation. By using different ratios of ethyl acetate and methanol (90 : 10, 80 : 20, 65 : 30 and 30 : 70, v/v), ACR and LID showed bad separation, and ACR was developed at lower R f than LID. It was concluded that by decreasing the ratio of ethyl acetate and increasing the ratio of methanol, the two components started to develop away from the baseline with poor resolution.
When 5% of acetic acid was added to the ratios of ethyl acetate and methanol, the separation was changed and ACR was developed at higher R f than LID due to the change in polarity of the developing system. The optimum developing system was ethyl acetate-methanolacetic acid in the ratio of 65 : 30 : 5 by volume.
Several wavelengths were tested for the determination of both ACR and LID (210, 220 and 254 nm), but ACR could not be well detected as it is highly fluorescent compound. The optimum way of detection was to measure ACR at 365 nm by adjusting the instrument at the fluorescent mode and measure LID at 220 nm by adjusting the instrument at the absorption mode.
Conclusion
The proposed work provided simple, sensitive, selective and accurate HPLC and TLC-densitometric methods for determination of ACR and LID in bulk powder and pharmaceutical formulation without interference from the excipients. The proposed methods were validated according to ICH guidelines and could be used for routine analysis of ACR and LID in quality control laboratories, where economy and time were essential. The proposed HPLC method could determine the related impurity of LID, which was very toxic. The proposed TLC-densitometric method had the advantages of short run time, large sample capacity and the use of minimal value of solvent.
